Literature DB >> 5338884

A clinical trial of four hypnotic drugs.

W H le Riche, A Csima, M Dobson.   

Abstract

A CLINICAL TRIAL OF FOUR HYPNOTIC DRUGS WAS CARRIED OUT: Ro 4-5360, 10 mg. (Mogadon), methyprylon, 200 mg. (Noludar), Ro 4-5360, 5 mg. (Mogadon), secobarbital sodium, 100 mg. (Seconal), and a placebo. The study was on the usual double-blind basis, and all observations were made by a full-time nurse. Capsules were given at 10 p.m. for five successive nights, with two nights free from medication or observation. There were five such periods. The nurse carried out her observations right through the night, determining whether the patients were awake or asleep. Each of these drugs was statistically significantly different from the placebo, in terms of length of sleep. Differences between the individual drugs were not significant. The length of action of the various drugs appeared to be similar, with a somewhat longer period of activity for the Mogadon in both dosages. The major side effect was some drowsiness: this was more marked with Mogadon 10 mg. With the hypnotics, the patients had, on the average, about one hour more sleep than on the placebo.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5338884      PMCID: PMC1935574     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  2 in total

1.  Clinical and statistical evaluation of six hypnotic agents.

Authors:  W le RICHE
Journal:  Can Med Assoc J       Date:  1963-04-20       Impact factor: 8.262

2.  A CLINICAL EVALUATION OF FOUR HYPNOTIC AGENTS, USING A LATIN-SQUARE DESIGN.

Authors:  W H LERICHE; A CSIMA
Journal:  Can Med Assoc J       Date:  1964-08-29       Impact factor: 8.262

  2 in total
  2 in total

1.  Nitrazepam in emotional disorders of childhood.

Authors:  A B Khorana
Journal:  Indian J Psychiatry       Date:  1981-01       Impact factor: 1.759

2.  Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program.

Authors:  D J Greenblatt; M D Allen
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.